2. Search Result
Search Result
Results for "

CDK2-IN-9

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101212
    Fadraciclib
    5+ Cited Publications

    CYC065

    		 CDK Cancer
    Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50s of 5 and 26 nM, respectively .
    Fadraciclib
  • HY-144811
    CDK2-IN-9

    		CDK Apoptosis Cancer
    CDK2-IN-9 is a potent CDK2 inhibitor with an IC50 of 0.63 µM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma .
    CDK2-IN-9
  • HY-181620
    CDK2 degrader 9

    		Molecular Glues CDK Cancer
    CDK2 degrader 9 (compound 1) is a CDK2-targeting Molecular Glue with selectivity for GSPT1 and CDK1. CDK2 degrader 9 promotes the ubiquitination and degradation of CDK2 via the ubiquitin ligase pathway. CDK2 degrader 9 is applicable to research related to cancer, solid tumors and hematologic malignancies .
    CDK2 degrader 9
  • HY-101212R
    Fadraciclib (Standard)

    CYC065 (Standard)

    		 CDK Reference Standards Cancer
    Fadraciclib (Standard) is the analytical standard of Fadraciclib (HY-101212). This product is intended for research and analytical applications. Fadraciclib (CYC065) is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK9 kinases with IC50s of 5 and 26 nM, respectively .
    Fadraciclib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: